Cramer P, von Tresckow J, Fink AM, Robrecht S, et al. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. Am J Hematol 2024 Apr 5. doi: 10.1002/ajh.27304.
PMID: 38578022